ROCKET PHARMACEUTICALS INC (RCKT) Stock News
NASDAQ:RCKT - Nasdaq - US77313F1066 - Common Stock - Currency: USD
RCKT Latest News, Press Relases and Analysis
Here are the top movers in Tuesday's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow
Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt research on its experimental gene therapy for Danon Disease. The decision comes on the experimental drug RP-A501, resulting in a serious adverse event that led to a patient’s demise. Likewise, Leerink Partners downgraded the stock to ‘Market Perform’ […]
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness) and intellectual disability. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The patient passed away after an acute systemic infection
William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback
Sami Corwin, an analyst at William Blair, maintained his Outperform rating on Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) on May 27 with no price target, despite the company’s recent difficulties. The biotechnology company’s trial for the gene therapy medicine RP-A501 was clinically halted and a patient tragically passed away. Corwin stated that the delay was required due […]
RCKT Stock Tanks on Patient Death in Danon Disease Study
Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.
Booz Allen, FreshPet, Rocket Pharma Downgraded, While Vail Resorts And FICO Get An Upgrade – Top Wall Street Analyst Calls Today
State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85.
Broadcom, Arista Networks initiated: Wall Street's top analyst calls
Broadcom, Arista Networks initiated: Wall Street's top analyst calls
Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery
Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers.
Mentions: MS
Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) has suspended dosing in its Danon disease gene therapy trial after a patient developed fatal complications from capillary leak syndrome, which caused a severe drop in blood pressure and led to an acute systemic infection. The FDA placed a formal clinical hold on the trial following the incident. The company is […]
There are notable gap-ups and gap-downs in today's session.
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Stay updated with the stocks that are on the move in today's pre-market session.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now?
We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stands against other best low priced biotech stocks to buy now. Is Now the Time to Buy Biotech Stocks? On May 8, Michael Yee, […]
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]
Mentions: TSLA
